922 results about "Intramuscular injection" patented technology

In an aspect, a medication delivering injector which includes a housing having opposing proximal and distal ends and an accessible internal cavity for inserting and removing a medicament container such as a syringe. The injector is designed to hold and manipulate a medication delivery device such as a large variety of standard and non-standard medical syringes with fixed or attached needles, assembled such that centrally located is a cylinder containing a liquid medicament and attached either permanently or removably to the distal end of the cylinder, is a hypodermic needle or cannula in fluidic communication with the cylinder. The needle can be from one-half inches to one-and-one-half inches in length in the illustrated embodiment and other sizes are possible by changes in scale of the injector. At the proximal end of the cylinder is an opening with an inserted seal or bung with an attached rod thus constituting a plunger. The central medicament containing cylinder could also be a standard medicament cartridge. Hereinafter, both are referred to as a “syringe”. A lid or access cover which, in an open position permits insertion and removal of the syringe into / from the housing in a horizontal fashion thus providing ease of loading. The syringe is inserted with the needle end toward the distal end of the housing and the plunger toward the proximal end of the housing. A movable carriage is disposed in the proximal end of the housing and slides in the axial direction forwards and rearwards such that a syringe, whose proximal end is gripped by the carriage, so moves with the carriage such that the needle exits the housing at the distal end of the housing and pierces the tissue of the patient prior to dispensing of the medicament, and then is retracted after the medicament has been dispensed by retraction of the carriage. Attached to the carriage is an actuator which pushes on the syringe plunger causing the medicament contained within the syringe cylinder to be dispensed through the needle into the patient's tissue. In one embodiment suitable for both removable needle and fixed needle syringes, the proximal end of the syringe including the syringe finger flange is gripped by an elastomeric flange grip which resides within the carriage, while the syringe distal end resides in and is supported by a “syringe guide” which is attached to the carriage and thus moved with it. In another embodiment which is so made to accommodate syringes with removable needles and their safe disposal, the syringe flange at the proximal end of the cylinder is gripped by an elastomeric flange grip which resides in the carriage as described above, while the syringe distal end is supported by a needle which resides in a removable disposable needle shield. The needle guide is biased toward the carriage and thus, the syringe body is compressed and guided as the carriage moves forward and rearward.Both the movement of the carriage and the actuator are controlled by servo motors which are controlled by electronics and a microcontroller so operating such that speeds and accelerations are controlled smoothly and gently so as to avoid the stop / start motion of motors controlled by limit switches and simple electronics or the vibration and abruptness such as result from injectors powered by compressed springs or gas. Furthermore, the forces are adaptive to the loads imposed and the requirements necessary for the proper dispensation of medicaments with high viscosity or sensitivity to shear forces.The housing, approximately midway between proximal and distal ends, is affixed by a hinge such that the device can be folded in half to provide for a more compact device to be stored and transported.On the distal end of the housing are electrical sensor pads in communication with the microcontroller such that contact with the patient's skin and the angle at which the injector is held against the skin and the steadiness with which the injector is being held can be ascertained. Within the housing are a haptic vibrator and an audio speaker, both producing a vibration which is variable in pitch in such a manner that biofeedback is provided to the injector user as to the pressure, angle and steadiness with which they are holding the injector against the skin. This facilitates the action of injection oneself in the gluteus muscle where visual feedback isn't available to the patient.Multiplexed onto the electrical sensor pads, is a TENS (Transcutaneous Electrical Nerve Stimulation) generator which is operational (at the user's choice) just before and during the injection to interrupt or quench the pain of tissue perforation often accompanied with needle injections.Contained on the surface of the housing such as on the access cover, is a display such that user menus, device state, directions, and battery charge status, etc. are displayed. Also contained on the surface of the housing, on the proximal half, are buttons which control the menus and selections that are shown on the display. These selections provide for the user to set such parameters as hypodermic insertion speed and medicament dispensing speeds, the preferred mode of user biofeedback which can include: speech mode (which can be accompanied by musical themes and ringtones, plus variable pitch tone and haptic vibration), MP3 mode (which has speech muted but includes musical ringtones and variable pitch tone and haptic vibration), and haptic mode (which is haptic vibration and audio tone queues needed for injector position biofeedback and readiness), plus mute mode (which provides no audio but the haptic vibration remains), and none, which provides no vibrational biofeedback, yet the display information always remains available.Also contained on the surface of the housing on the distal half, is an “injection initiate” button which causes the sequences required for performance of an injection to occur if said button is “enabled”.Contained within the electronics and its operating program is the ability to audibly play pre-recorded human speech in any language such that: directions in the form of consecutive steps which are required to load the medicament container (syringe) into the device, consecutive steps to perform an injection, steps to remove and properly dispose of parts, to alert of device status and menu choices, etc. can be played through the audio speaker. Also contained within the electronics and program is the ability to play musical ringtones as a distraction during the needle insertion and injection or when a scheduled injection alarm is reached, or calming human voice exhibiting bedside manner during the needle insertion and injection.Also contained within the electronics and software is a real-time clock-calendar which can store a patient's injection schedule and play a musical ringtone as an alarm as each scheduled injection becomes due. Also contained within the electronics and software are the ability to communicate with a personal computer through a USB port, which can also charge the injector's rechargeable battery. The battery in one embodiment, consists of three AAA batteries which can be rechargeable or non-rechargeable. The USB port in combination with an application running on the personal computer, is used to download the injection schedule into the real-time clock-calendar and to download ringtones and musical themes of the user's choice and to download foreign language sets for the pre-recorded human language feature.The injector can be further equipped with the capability to aspirate the tissue by drawing back on the plunger thus creating a vacuum into which fluids will flow. These fluids enter the syringe cylinder where they can be checked for the presence of blood by optical absorption in the red spectrum. This information is useful in the instances where intramuscular injections are to be given with drugs whose ‘Full Prescribing Information’ instructs the patient to aspirate and check for blood in the syringe which indicates that the puncture of a vein has occurred, and if so detected, to abort the injection and then re-inject into a different location.

An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.

A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range.

The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

The invention discloses the components and preparation method of beta-lactam injection. The beta-lactam injection comprises 5 to 20 percent of beta-lactam antibiotics, 0.05 to 5 percent of suspending agent, 0.005 to 0.3 percent of antioxygen, 0.1 to 0.2 percent of nonionic surfactant and the balance of vegetable oil or grease for injection. The injection can be used for preventing and curing animal bacterial infectious diseases and can be injected hypodermically or in muscle and be applied through breast for a few times. The preparation method provided by the invention comprises: firstly, making the antibiotics and the antioxygen into micro powder and making the suspending agent into fine powder; secondly, adding the vegetable oil or grease for injection, which is sterilized at high temperature, into the fine powder of the suspending agent, heating the mixture, uniformly mixing the mixture and keeping the mixture in a sterile environment to cool the mixture to room temperature for later use; and finally, transferring the prepared oil or grease added with the suspending agent to a colloid mill, adding medicament micro powder, the antioxygen and the non-ionic surfactant with stirring, and performing uniform mixing and sterilization to obtain the beta-lactam injection.

Pharmaceutical compositions are provided for the treatment of steroid-dependent and other diseases. The compositions are solutions for subcutaneous or intramuscular injection, and the active agent is a GnRH antagonist peptide according to general formula (1): Ac-DNal-DCpa-DPal-Ser-Aph(X1)-DAph(X2)-Leu-Lys(iPr)-Pro-DAla-NH2 present at a concentration sufficient to from a gel following administration.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

The present invention provides adeno-associated viral (AAV) vectors encoding an angiostatin protein ("AAV-angiostatin vector") and / or a costimulatory molecule B7.1 ("AAV-B7.1 vector"). The AAV-angiostatin vector can be administered to a subject, alone or in combination, sequentially or simultaneously, with a AAV-B7.1 vector for treatment, management or prevention of metastatic tumors. Pharmaceutical compositions and vaccines comprising the AAV-angiostatin vector and / or the AAV-B7.1 vector and methods of manufacturing are also described. Administration of AAV-angiostatin and AAV-B7.1 vectors by intraportal and muscular injections are also provided.

The invention relates to a nanocomposite temperature-sensitive gel and a preparation method and an application thereof. The preparation method comprises the following steps of: coating antitumor active substances with a high molecular polymer serving as a carrier material to obtain nanoparticles; and adding a temperature-sensitive high molecular material to obtain the nanocomposite temperature-sensitive gel. The preparation method disclosed by the invention is simple and convenient, is suitable for large-scale production, and is particularly suitable for preparing medicaments or diagnostic reagents having the characteristics of long cycle, biodegradability, slow release, passive targeting, active targeting, active substance conveying function and tumor resistance. An antitumor medicament prepared with the method disclosed by the invention is suitable for ways such as intravenous injection, intramuscular injection, hypodermic injection, intradermal injection, intratumor injection, tumor-side injection, oral administration or transdermal medicament delivery and the like, is applied to treatment and diagnosis of pancreatic cancer, liver cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer, prostatic cancer, uterine cancer and ovarian cancer, and has a good application prospect.

A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks.

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and / or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

The invention provides therapeutic antimicrobial compositions and methods for their use based on natural organic phenolic compounds combined with pharmacological agents. The antimicrobial activities of each carvacrol and thymol are believed to be enhanced, while the pharmacological properties of procaine and related compounds are added to provide their unique properties to facilitate usefulness and effectiveness in humans. The therapeutic compositions are active against bacterial, fungal, and protozoan infections. The forms of the invention are intended to treat various internal infections through parenteral, subcutaneous, intradermal, intravenous, and intramuscular injections. They are also intended as useful agents to treat microbial infections that have become resistant to conventional anitibiotics as well as secondary opportunistic infections.

Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg / ml in the absence of castor oil and castor oil derivatives are disclosed.

A buttocks intramuscular injection training model is provided. The buttocks intramuscular injection training model includes a hip model having a similar shape to a human hip; injection modules inserted into both sides of the hip model and each being configured to comprise electrode layers to detect a needle and a muscle layer into which injection liquid is injected; a controller connected to the electrode layers to detect a location of the needle; and an input and output device wired or wireless connected to the controller for bidirectional communication with the controller and configured to visibly output the location of the needle.

The invention pertains to biological genetic engineering field, specificly relating to SARS vaccine of adenovirus carrier and preparation method, application of related coronavirus S gene in preparation of the SARS vaccine for preventing SARS. Through a bioengineering means, the related coronary virus S gene and a defective adenovirus are recombined, which makes protective immunogen protein or polypeptide expressing in it. A genic vaccine that can arouse the mucosal immunogenicity is produced through amplifying training, purification, and preparation, which induces a immunity reaction in the respiratory mucosa, makes the organism produce the corresponding antibody, and prevents virus from infection. Compared with the traditional inactivated viral particles vaccine, the invention has a high safety; it is convenient to operate; it is not limited by the specific conditions such as intramuscular injection; and it has an extensive clinical application prospect.

The present invention discloses one medicinal polymer (PELGE / PELGA) nanometer particle carrier and its preparation process and use. The carrier material is PELGE material of different molecular weights, different LA / GA ratios and different PEG contents, and the nanometer PELGE / PELGA carrier particle is prepared through evaporation process. The said copolymer is self-assembled in water into nanometer particle or micelle, and its hydrophobic PLGA segment coagulates into the core while the hydrophilic polyglycol forms hydrophilic shell. The carrier may be used for the nanometer preparation of plasmid, nucleic acid vaccine, antisense oligodeoxynucleotide or ribozyme for genetic treatment; the nanometer preparation of various chemical medicines; and the nanometer preparation of polypeptide and protein medicines.

The invention belongs to an autolytic microneedle in the technical field of transdermal drug delivery and especially relates to an autolytic microneedle transdermal patch and a preparation method thereof. In the invention, endogenic oligomerized hyaluronic acid and / or low-molecular-weight heparan sulfate are employed as a microneedle substrate material and a vaccine adjuvant at the same time to prepare the autolytic microneedle in which a vaccine is loaded, thereby preparing the autolytic microneedle transdermal patch in the invention. The autolytic microneedle transdermal patch can achieve effective transcutaneous immune of the vaccine and enhance humoral immune response of the vaccine. Compared with intramuscular injection immune and other autolytic microneedle transcutaneous immune in the prior art, the autolytic microneedle transdermal patch can significantly enhance cellullar immunologic response of the vaccine.

The invention discloses a nano aluminum-encapsulating carrier and an application of the nano aluminum-encapsulating carrier in constructing a vaccine adjuvant transfer system. The nano aluminum is nanoparticles of aluminum phosphate, aluminum sulfate and aluminum hydroxide or a mixture of aluminum phosphate, aluminum sulfate and aluminum hydroxide, wherein the grain size is below 1 mu m; the carrier is a lipidosome, a lipoid, an emulsion, a nano-capsule or a micro-capsule. Construction of the vaccine adjuvant transfer system is the main purpose of the nano aluminum-encapsulating carrier. The application of the nano aluminum-encapsulating carrier in constructing the vaccine adjuvant transfer system comprises the following step: encapsulating vaccine components in the nano aluminum-encapsulating carrier; or adsorbing the vaccine components on the surface of the carrier; or purely mixing with the carrier to exert the vaccine adjuvant and the transfer function. The nano aluminum-encapsulating carrier disclosed by the invention has the advantages that the nano aluminum-encapsulating carrier is wide in application range, so that the nano aluminum-encapsulating carrier is suitable for antigens with different pathogens; the nano aluminum-encapsulating carrier is high in stability and can encapsulate antigens so as to enhance in vivo and in vitro stability; the nano aluminum-encapsulating carrier is high in safety, and the use materials have good biocompatibility; the nano aluminum-encapsulating carrier is many in inoculation and wide in way, and the carrier can be inoculated through track mucosa or subcutaneous, intracutaneous and intramuscular injection; the carrier is strong in immunosuppression induction potency.

The invention provides an in-situ phase change gel slow release system taking a phospholipid as a substrate, and provides a preparation method thereof. A high-concentration phospholipid slow release preparation is prepared from a high-concentration (50-85 percent) phospholipid, a bioactive ingredient, ethanol solutions of different concentrations and / or injection oil with a simple method, and has the characteristics of high biocompatibility, small untoward effect, remarkable slow release effect and suitability for various administration forms such as hypodermic injection, intramuscular injection, external administration and the like; the amount of a coated medicament can be conveniently adjusted according to the clinical dosage of a medicament; and the in-situ phase change gel slow release system has a wide application prospect.

The invention provides a lightweight, inexpensive syringe holder for substantially simultaneous multiple injections such as, but not limited to, intramuscular injections for immunizations. The syringe holder can be molded as a single unit, and can be disposable or reusable, and easily cleanable and / or sterilizable, as desired. The syringe holder can securely accommodate two or more syringes, and two or more substantially simultaneous injections can be performed easily by the administrator using only one hand. Thus, it is possible for the administrator to use two hands, and perform four or more injections that are substantially simultaneous, thus reducing pain, stress and trauma.

A composite liquid biphenyl dimethyl dicarboxylate and its emulsion and oil injections for intravenous injection, intramuscular injection, or oral application are disclosed. Said emulsion has high stability and low granularity. Said solution-type oil has slow releasing effect.

The invention relates to a biodegradable amphiphilic albumin derivative and a pharmaceutical composition thereof. In the biodegradable amphiphilic albumin derivative, hydrophilic long-chain polyethyleneglycol and alkyl (acyl) group or (deoxidized) cholic acid are led to an albumin skeleton so that the amphiphilic albumin derivative is amphipathic and is self-assembled in water to form nano-micelle. The biodegradable amphiphilic albumin derivative is characterized in that medicament can be encapsulated through the double actions of a hydrophobic group and an albumin molecule chain with the medicament, and the capacity of the albumin encapsulating the medicament is markedly improved; in addition, a hydrophilic long-chain can reduce the immunogenicity of the albumin and improve the nano-micelle surface hydrophilicity so that the stability of the nano-micelle in aqueous medium can be improved and the nano-micelle has long-circulation characteristics in a body. The pharmaceutical composition of the biodegradable amphiphilic albumin derivative can be used as the carrier of organic medicament, water-insoluble or insoluble medicament and amphiphilic medicament, can be used for intravascular administration, intramuscular injection administration, oral administration, cavitary administration or external administration. The invention can be prepared with simple method and mature process and is suitable of large-scale continuous production.

Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and / or high-molecular-weight proteins, such as mAbs, and viscosity-lowering water soluble organic dyes.

The invention discloses an andrographolide suspension capable of obviously improving oral bioavailability and realizing slow release by intramuscular injection or hypodermic injection, a method for preparing the suspension and a medical application of the suspension. The preparation consists of a general suspension and a dry suspension and can be taken orally or subjected to hypodermic injection or intramuscular injection. The method is characterized in that the raw materials are processed to obtain micron-sized or nanometer-sized particles, a certain amount of auxiliary materials are added, thus the bioavailability is improved and the stability of the preparation is ensured. The whole preparation process is simple and controllable, and the industrial production can be realized. Compared with a preparation prepared from common raw materials, the preparation prepared by the preparation method, disclosed by the invention, has the advantages that the bioavailability can be obviously improved by taking orally; and the low release effect can be realized after intramuscular injection or hypodermic injection.

The invention relates to a device for injecting veterinary products to at least one bird by intramuscular injection, wherein said injection(s) can be carried out in the area of at least one muscle in the vicinity of a bone having a detectable shape in the body of said poultry, said device comprising: a retention member with means for bracing said detectable bone, at least one hole being formed in said retention member; at least one injection needle, said needle(s) being movable across said opening(s); characterized in that the retention member has: an anatomic shape that conforms to a portion of the body of said poultry and inside which is provided said means or bracing the detectable bone, said anatomic shape including a bearing surface for said body at said muscle; at least two contact sensors to be actuated by said poultry and provided on the anatomic shape with at least one on the bearing surface, said opening(s) being provided between said sensors.

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

The invention relates to a bio-degradable alb derivative and the related pharmaceutical combinations; wherein, the derivative introduces alkyl, or fatty acyl or deoxycholic acid in the alb skeleton to enable the amphiphilic property and form a nano-micelle by self-organization in water, and can enwrap the drugs through the double effects of the hydrophobic group, the alb molecular chain and the drugs, thereby substantially improving the drug enwrapping ability of the alb and prolonging the stability time. The excipient can be used as the carrier for organic drugs, water-insoluble drugs or dugs with poor water solubility and the carrier of amphipathic drugs, and for the administration inside the vein or muscle injection and oral administration. The preparation method of the bio-degradable alb derivative and the related pharmaceutical combinations is simple and of mature techniques, which is suitable for large scale continuous production.